Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trialSanjay Ramakrishnan, Mona Bafadhel, Jodie L. Simpson et al.|The Lancet Respiratory Medicine|2021Cited by 434
Challenges for inhaled drug discovery and development: Induced alveolar macrophage responsesBen Forbes, Alison Wolfreys, Raegan O’Lone et al.|Advanced Drug Delivery Reviews|2014Cited by 91
Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroid‐independent mechanismSamuel Chao Ming Yeo, Louise Donnelly|British Journal of Pharmacology|2017Cited by 74
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysisJonathan Baker, Mona Bafadhel, Mahdi Mahdi et al.|The Lancet Respiratory Medicine|2022Cited by 58
Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trialSanjay Ramakrishnan, Mona Bafadhel, Dan V. Nicolau et al.|medRxiv|2021Cited by 25